MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-18-2023
Aptinyx Retained Earnings 2011-2026 | APTX
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Aptinyx
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -353 M | -288 M | -213 M | -163 M | -106 M | -52.3 M | -20.2 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -20.2 M | -353 M | -171 M |
Quarterly Retained Earnings Aptinyx
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -374 M | -353 M | -341 M | - | -308 M | -288 M | -268 M | -247 M | -227 M | -213 M | -213 M | -213 M | -213 M | -163 M | -163 M | -163 M | -163 M | -106 M | -106 M | -106 M | -106 M | -52.3 M | -52.3 M | -52.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -52.3 M | -374 M | -195 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
-972 M | $ 2.08 | -14.4 % | $ 214 M |  USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Altimmune
ALT
|
-561 M | $ 4.2 | -2.67 % | $ 298 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
-3.01 B | $ 20.24 | -3.44 % | $ 2.55 B | USA |
 |
Aptorum Group Limited
APM
|
-72.4 M | $ 0.8 | 1.87 % | $ 4.36 M |  China |
 |
Aprea Therapeutics
APRE
|
-308 M | $ 0.88 | -3.72 % | $ 3.18 M | USA |
 |
Aptevo Therapeutics
APVO
|
-248 M | $ 7.2 | -1.64 % | $ 1.99 M | USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M | China |
 |
Aquestive Therapeutics
AQST
|
-363 M | $ 4.1 | 2.37 % | $ 356 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-449 M | $ 8.35 | 1.46 % | $ 225 M |  Israel |
 |
Ardelyx
ARDX
|
-947 M | $ 6.37 | -2.75 % | $ 1.54 B | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
argenx SE
ARGX
|
-861 M | $ 756.71 | -1.33 % | $ 25 B |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
-309 M | $ 10.91 | 1.58 % | $ 394 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-1.14 B | $ 25.33 | -6.1 % | $ 3.22 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Artelo Biosciences
ARTL
|
-63 M | $ 1.15 | -3.36 % | $ 2.32 M | USA |
 |
Arvinas
ARVN
|
-1.61 B | $ 12.97 | -2.3 % | $ 920 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
-1.63 B | $ 61.74 | -2.42 % | $ 8.26 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 231.56 | -0.83 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.39 | -1.63 % | $ 8.16 B |  Australia |
 |
Actinium Pharmaceuticals
ATNM
|
-376 M | $ 1.17 | -0.85 % | $ 35.2 M | USA |
 |
Atossa Therapeutics
ATOS
|
-186 M | $ 4.39 | -0.9 % | $ 553 M | USA |
 |
Atara Biotherapeutics
ATRA
|
-2.05 B | $ 5.01 | -7.47 % | $ 37.5 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
-649 M | $ 14.14 | -0.21 % | $ 1.9 B |  Canada |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.1 B | $ 1.68 | -1.75 % | $ 429 M | Britain |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
Atea Pharmaceuticals
AVIR
|
-364 M | $ 4.69 | 0.21 % | $ 395 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
-223 M | - | 1.93 % | $ 17.4 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-382 M | $ 4.54 | 2.44 % | $ 387 M | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
Axon Enterprise
AXON
|
812 M | $ 570.5 | 5.18 % | $ 43.2 B | USA |
 |
Axsome Therapeutics
AXSM
|
-1.31 B | $ 162.28 | -0.98 % | $ 8.07 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.56 | -0.58 % | $ 16.1 M | USA |
 |
Aileron Therapeutics
ALRN
|
-351 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |